PDAC
Clinical trials for PDAC explained in plain language.
Never miss a new study
Get alerted when new PDAC trials appear
Sign up with your email to follow new studies for PDAC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control ApprovedThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Matched conditions: PDAC
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo aims to boost Chemotherapy's punch against pancreatic cancer
Disease control OngoingThis trial tests whether adding an experimental drug called AMP945 to standard chemotherapy (nab-paclitaxel and gemcitabine) can improve tumor shrinkage in people with advanced pancreatic cancer that cannot be removed by surgery. The study has two parts: first, finding the best d…
Matched conditions: PDAC
Phase 1/2 • Sponsor: Amplia Therapeutics Limited • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug enters final testing phase
Disease control OngoingThis phase 3 trial tests a new drug called daraxonrasib (RMC-6236) against standard treatments for people with metastatic pancreatic cancer that has already been treated. About 500 adults with a specific RAS gene mutation will be randomly assigned to receive either the new drug o…
Matched conditions: PDAC
Phase 3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Can digestive enzymes help pancreatic cancer patients keep weight on?
Disease control OngoingThis study tests whether taking pancreatic enzymes (Pertzye) with meals can help people with metastatic pancreatic cancer maintain their body weight during chemotherapy. The trial includes 17 participants who are starting a standard chemo regimen called FOLFIRINOX. Researchers wi…
Matched conditions: PDAC
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC